Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospekta for Post-COVID-19 Asthenia
NCT05074888Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post acute COVID-19 syndrome comparing Prospekta with Placebo (2 arms). Primary endpoint: Change in the Mean Fatigue Severity Scale Score at 4 weeks. Started Oct 2021; status: completed.
02
Drugs
Prospekta
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT05074888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074888.